Quintrio
Home

SURGICAL & MEDICAL INSTRUMENTS & APPARATUS

Intelligent Bio Solutions Inc. Common Stock

INBS

Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.

Last trade $1.55
Day change +$0.05 (+3.33%)
Day range $1.52 – $1.61
Volume 41,158
Market cap $5M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$4.98M
Price / earnings
—
Price / book
0.66×
Price / sales
1.11×
EV / sales
-0.21×
EV / EBITDA
0.09×

Profitability

Earnings per share
-$3.65
Return on assets
-88.88%
Return on equity
-159.66%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.98×
Quick ratio
1.87×
Cash ratio
1.3×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$11.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for INBS, quarterly periods
Line itemQ1 FY2027 Sep 30, 2026Q4 FY2026 Jun 30, 2026Q3 FY2026 Mar 31, 2026Q2 FY2026 Dec 31, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q3 FY2025 Mar 31, 2025Q2 FY2025 Dec 31, 2024
Revenue$1.39M$1.15M$1.06M$896.77K$1.11M$843.88K$728.87K$607.49K
Cost of revenue$633.83K$609.22K$525.42K$437.04K$593.51K$508.31K$387.5K$384.38K
Gross profit$758K$536.58K$535.38K$459.74K$518.29K$335.58K$341.37K$223.11K
Selling, general and administrative$2.58M$2.99M$2.46M$2.34M$2.71M$2.72M$2.41M$1.81M
Research and development$829.54K$1.47M$893.98K$522.11K$486.17K$582.47K$358.35K$506.94K
Total operating expenses$3.44M$4.51M$3.48M$3.1M$3.52M$3.44M$2.9M$2.49M
Operating income-$2.68M-$3.97M-$2.95M-$2.64M-$3M-$3.11M-$2.56M-$2.26M
Interest expense-$1.44K-$3.3K-$4.24K-$56.21K-$2.31K-$5.31K-$7.92K-$13.5K
Income before taxes-$2.67M-$3.92M-$2.87M-$2.69M-$2.99M-$3.1M-$2.55M-$2.26M
Income taxes$0$0$0$0$0$0$0$0
Net income-$2.67M-$3.92M-$2.87M-$2.69M-$2.99M-$3.1M-$2.55M-$2.26M
Net income attributable to common shareholders-$2.66M-$3.91M-$2.86M-$2.68M-$2.98M-$3.09M-$2.54M-$2.25M
EBITDA-$2.39M-$3.68M-$2.65M-$2.28M-$2.44M-$2.59M-$2.26M-$1.9M
Basic earnings per share-$0.86-$1.57-$1.80-$2.82-$3.49-$4.43-$4.41-$4.96
Diluted earnings per share-$0.86-$1.57-$1.80-$2.82-$3.49-$4.43-$4.41-$4.96

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Intelligent Bio Solutions Announces Closing of $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Intelligent Bio Solutions Inc. (INBS) closed a $10.0 million private placement with two healthcare-focused institutional investors, issuing 2,298,850 shares of common stock at $4.35 per share along with Series K-1 and K-2 warrants. The company plans to use proceeds for working capital, FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System, and international market expansion.

Benzinga

Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In Focus

U.S. stock futures rose on the first trading day of 2026, with the S&P 500 and Nasdaq 100 gaining in premarket trading. Key movers included Baidu jumping 12.2% on a spinoff announcement, Rubico surging 16.8% following an acquisition deal, while Outlook Therapeutics plummeted 56.5% after an FDA rejection and Intelligent Bio Solutions dropped 23.4% on a private placement announcement. Analysts predict modest 3-5% gains for 2026 after a record-breaking 2025.

GlobeNewswire Inc.

Intelligent Bio Solutions Announces $10.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Intelligent Bio Solutions Inc. (INBS) announced a $10.0 million private placement of 2,298,850 shares of common stock and warrants priced at $4.35 per share to two healthcare-focused institutional investors. The company plans to use net proceeds for working capital and general corporate purposes. Closing is expected on or about January 2, 2026, with Ladenburg Thalmann & Co. Inc. serving as the exclusive placement agent.

GlobeNewswire Inc.

Intelligent Bio Solutions Adds Quantum TM to 400+ Account Portfolio Utilizing Breakthrough Fingerprint Drug Testing

Intelligent Bio Solutions Inc. (INBS) announced that Quantum Traffic Management (Quantum TM), a UK-based traffic management provider, has adopted INBS' Intelligent Fingerprinting Drug Testing Solution across its 10 nationwide sites. The fingerprint-based system enables Quantum TM to conduct on-the-spot drug screening in-house, improving testing efficiency and productivity.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Dec 16, 20251-for-10reverse split
Jan 29, 20241-for-12reverse split
Feb 10, 20231-for-20reverse split